study we cannot confirm that the phase of the menstrual cycle during surgery has any effect on the eventual outcome in mammary carcinoma patients. However larger studies of this type are required before definitive conclusions can be reached.
Several investigators have reported a relationship between prognosis and the phase of the menstrual during operation for patients with mammary carcinoma. In particular, patients surgically treated in the perimenstrual period (days 0-6 and 21-36) have been reported to have a poorer prognosis Badwe et al., 1991; Gregory et al., 1992) . Other groups have not been able to confirm these findings (Powles et al., 1991; Rageth et al., 1991; Gnant et al., 1992 ). An important drawback of these studies is their retrospective character with all its possible disadvantages (Forbes, 1991) . One of the shortcomings of retrospective studies in this respect is the inaccurate estimation of the first day of the last menstruation since this is not always recorded exactly in charts and progesterone (P) were determined, using assay procedures described previously (Thomas et al., 1977 lected daily from 50 women throughout one ovulatory cycle. Based on these data the patients participating in the present study could be categorised into the three groups comprising, respectively, 24, 36 and 29 patients (Table I ).
In contrast to other studies, we designated the day of ovulation as the first day of the menstrual cycle and not the first day of menstruation.
All patients <T3 underwent either a modified radical mastectomy or a breast conserving procedure (TI-Tu). In patients with a T4 tumour a lumpectomy was performed without axillary clearance. If they were free of disease after locoregional treatment they were included in the study. As a rule axillary irradiation was applied in case of extranodal axillary involvement. All node-positive women (46) received six courses of adjuvant chemotherapy (cyclophosphamidemethotrexate-5-fluorouracil). The receptor status of the tumour was available for 78 patients of this series. The estimated disease-free survival was calculated according to the Kaplan-Meier method. The median follow-up period was 4.1 years. Table II shows some tumour characteristics of the three different groups. In each of the three groups the distribution over the various tumour stages was similar. In addition, no differences between groups were observed regarding receptor status. Seven out of 24 (29%) of the preovulatory patients, 7 out of the 36 (19%) patients from the periovulatory group, and 10 out of the 29 (34%) patients from the post-ovulatory (Figure 1) . Also, in the No and the N, subgroups no difference in survival was found between the phase groups (P = 0.22 and P = 0.58 respectively, log-rank test).
Results

Discussion
No relationship between the phase of the menstrual cycle at the time of primary surgical treatment of patients with mammary carcinoma and the outcome could be demonstrated in our patient group. Furthermore, no differences were found between the No and the N1 subgroups in any of the three groups. The latter finding is in contrast to observations by Senie et al. (1991) .
The main difference between our study and those published previously by other investigators is the method of establishing the phase of the menstrual cycle. In all these studies except one (Ville et al., 1991 ) the phase of the cycle was calculated from data mentioned in the patients' charts, while we determined the phase of the cycle biochemically on the basis of the hormonal pattern. In this way we were able to categorise patients exactly as being in the preovulatory (proliferative, follicular) phase (day -12 to -3), the periovulatory phase (day-3 to +1) or the post-ovulatory (secretory, luteal) phase (day + 1 to + 12). This method is more reliable than assessing the phase on the basis of data recorded in menstrual charts. There is always some interindividual difference in the length of the menstrual cycle, particularly the preovulatory phase. Therefore the exact phase of the cycle may be calculated wrongly, inducing a , preovulatory phase; . periovulatory phase; ---, post-ovulatory phase.
certain bias (Senie et al., 1991) . Our negative finding concerning the relationship between phase and survival is in agreement with two other studies in which the patients were divided into a proliferative (follicular) and a secretory (luteal) group (Rageth et al., 1991; Senie et al., 1991) . It thus seems hard to defend the view that the unopposed oestrogen phase is a dangerous period during which patients with mammary carcinoma should not be subjected to surgery. If this theory were true post-menopausal women, who from a hormonal point of view most resemble women in the proliferative phase, would display a worse prognosis than premenopausal women. Moreover, the fact that almost half of premenopausal women would by chance undergo surgery during the proliferative phase of the menstrual cycle should have a clear impact on the survival of all premenopausal women compared with post-menopausal women.
We admit that our study group is small and that a larger group of patients should be investigated in order to give definitive conclusions. To have an 80% chance of detecting a difference of 50% in recurrence or death rate between the follicular and luteal phase groups as suggested by Gregory et al. (1992) , at least 200 recurrences or deaths would be required. Our small study may contribute to the discussion in a different way from retrospective studies, which also have limitations.
On the basis of our data there is no support for the finding of others that the perioperative phase of the menstrual cycle has an influence on the disease-free survival of patients with mammary carcinoma. However, larger studies of this type are required before definitive conclusions can be reached.
